SWOG clinical trial number
SWOG-8931 (INT-0108) (EST-3189)

Comparison of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil (CAF) and a 16-Week Multi-Drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node-Positive Breast Cancer

Closed
Phase
Published
Abbreviated Title
Comparison of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil (CAF) and a 16-Week Multi-Drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node-Positive Breast Cancer
Activated
07/15/1990
Closed
04/29/1993

Research committees

Breast Cancer

Publication Information Expand/Collapse

1998

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An intergroup study.

JH Fetting;R Gray;DL Fairclough;TJ Smith;KA Margolin;ML Citron;M Grove-Conrad;D Cella;K Pandya;N Robert;IC Henderson;CK Osborne;MD Abeloff Journal of Clinical Oncology 16(7):2382-2391

1995

CAF vs 16 week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: An Intergroup study.

J Fetting;R Gray;M Abeloff;B Fowble;T Smith;S Vail;G Durrani;L Eudey;J Henney;K Margolin;M Citron;C Osborn;C Henderson American Society of Clinical Oncology 14(#83):96

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase